- Home
- OTLK vs RPTX Comparison
OTLK vs RPTX Comparison
Compare OTLK & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- RPTX
- Stock Information
- Founded
- OTLK 2010
- RPTX 2016
- Country
- OTLK United States
- RPTX Canada
- Employees
- OTLK N/A
- RPTX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- RPTX Health Care
- Exchange
- OTLK Nasdaq
- RPTX Nasdaq
- Market Cap
- OTLK 64.6M
- RPTX 54.4M
- IPO Year
- OTLK 2016
- RPTX 2020
- Fundamental
- Price
- OTLK $1.83
- RPTX $1.18
- Analyst Decision
- OTLK Strong Buy
- RPTX Strong Buy
- Analyst Count
- OTLK 5
- RPTX 3
- Target Price
- OTLK $21.00
- RPTX $7.00
- AVG Volume (30 Days)
- OTLK 892.5K
- RPTX 409.8K
- Earning Date
- OTLK 02-12-2025
- RPTX 02-26-2025
- Dividend Yield
- OTLK N/A
- RPTX N/A
- EPS Growth
- OTLK N/A
- RPTX N/A
- EPS
- OTLK N/A
- RPTX N/A
- Revenue
- OTLK N/A
- RPTX $66,524,000.00
- Revenue This Year
- OTLK N/A
- RPTX $11.80
- Revenue Next Year
- OTLK $396.84
- RPTX N/A
- P/E Ratio
- OTLK N/A
- RPTX N/A
- Revenue Growth
- OTLK N/A
- RPTX 18.19
- 52 Week Low
- OTLK $0.87
- RPTX $1.10
- 52 Week High
- OTLK $12.85
- RPTX $8.49
- Technical
- Relative Strength Index (RSI)
- OTLK 39.18
- RPTX 35.97
- Support Level
- OTLK $1.79
- RPTX $1.10
- Resistance Level
- OTLK $2.26
- RPTX $1.27
- Average True Range (ATR)
- OTLK 0.18
- RPTX 0.07
- MACD
- OTLK 0.00
- RPTX 0.05
- Stochastic Oscillator
- OTLK 6.09
- RPTX 46.15
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.